Journal of Clinical & Experimental Dermatology Research
Open Access

Depression in patients with psoriasis: Effects of biologics

6^th International Conference on Clinical and Experimental Dermatology

May 04-06, 2016 Chicago, USA

Aymen El Gendy

Zagazig University, Egypt

Posters & Accepted Abstracts: J Clin Exp Dermatol Res

Abstract :

Psoriasis is a common chronic immune-mediated inflammatory disorder affecting 2-3% of the population. Psoriasis is associated with a variety of psychological difficulties including poor self-esteem, social stigmatization, anxiety, depression and suicidal ideation. Psoriasis is associated with substantial impairment of health-related quality of life (HRQOL). Some studies estimated that around one-quarter of patients in dermatology practices has a psychiatric disorder. Significantly elevated concentrations of TNF-�± have been observed in the plasma of patients with psoriasis and in patients with major depression. TNF-�± has been implicated in the pathogenesis of both psoriasis and depression. In humans, administration of TNF-a blockers such as etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) and IL-12/23 inhibitors have been found to improve depression that accompany psoriasis.

Biography :

Email: aymanelgendy91@yahoo.com